BRIEF-FDA grants accelerated approval to Durvalumab for treatment of patients with locally advanced or metastatic urothelial carcinoma

* Grants accelerated approval to Durvalumab for treatment of

patients with locally advanced or metastatic urothelial

carcinoma

Read more